SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Cyteir Therapeutics, Inc. (CYT) .
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($2.00, 33.8%).
- Analyst consensus target $2.00 (-33.8% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 25/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CYT
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.25
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$2.00 (-33.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.77 |
$8K |
$-15.04M |
-188050% |
| 2020 |
$-0.87 |
$0.00 |
$-20.82M |
- |
| 2021 |
$-2.14 |
$0.00 |
$-41.65M |
- |
| 2022 |
$-1.25 |
$0.00 |
$-43.95M |
- |
